ArticleInternational journal of preventive medicine2026
Designing the Data Elements for Patient Registry System for Membranous Nephropathy in Isfahan Province.
Article in International journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Membranous nephropathy is one of the most common glomerulonephritis types in adults. Various treatment methods are applied for this disease. Establishing a patient registry system and analyzing the collected data can help identify the strengths and limitations of current treatment approaches. This enables the adoption of more effective therapies, preventing disease progression to end-stage renal disease. Furthermore, consolidating patient information into a unified electronic system has diverse applications. Methods: This action research study utilized patient medical records (including hospital files, clinic cards, test reports, and prescriptions) as the primary data sources. In cases of incomplete information, data were collected from patients or their close relatives. Patient information was gathered using a checklist. Data analysis employed tests as necessary, depending on the objectives. Results: The final version of the checklist consisted of three sections: demographic variables (age, gender, education level, residence, date of birth, occupation, and contact information), laboratory tests, pharmaceutical variables, and treatment protocols used for patients. This information was systematically collected for all patients. Conclusions: Establishing a registry for membranous nephropathy in Isfahan is critical in improving treatment and control of this disease within the Iranian population. Comparing this data with similar studies from other regions can reveal epidemiological and clinical differences, which can be leveraged to enhance diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.